Menzies-Gow, Andrew <br/><br/>
Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics.  [electronic resource] 

 -  The Journal of allergy and clinical immunology  Apr 2003 
 - 714-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0091-6749 
<br/><br/><label>Standard No.: </label>10.1067/mai.2003.1382  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antigens, CD34--analysis<br/>Asthma--blood<br/>Bone Marrow Cells--drug effects<br/>Bronchi--drug effects<br/>Double-Blind Method<br/>Eosinophils--drug effects<br/>Hematopoietic Stem Cells--drug effects<br/>Humans<br/>Interleukin-5--analysis